Covestro (1COV) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
18 Jan, 2026Executive summary
Q3 2024 saw strong volume growth of 6.1% year-over-year, with sales at €3.6 billion, as higher volumes offset lower prices and unfavorable FX effects.
EBITDA reached €287 million, within guidance, but margins remain historically low due to negative pricing delta and weak industry demand.
Free operating cash flow was €112 million in Q3, but -€164 million for 9M 2024, reflecting lower cash flows from operations.
Significant progress on climate neutrality, with major projects reducing Scope 1 and 2 emissions, including catalyst installation in China, solar PPA in Spain, and a heat battery in Germany.
The takeover process with ADNOC is underway, with a public offer at €62.00 per share and a planned 10% capital increase; acceptance period runs until November 27, 2024.
Financial highlights
Q3 2024 sales were €3.6 billion (+1.0% YoY), driven by 6.1% volume growth offsetting a 4.2% price decline and negative FX.
EBITDA increased 3.6% year-over-year to €287 million.
Free operating cash flow for Q3 was €112 million; 9M 2024 free operating cash flow was -€164 million.
Net debt increased by €159 million since end of 2023; net debt/EBITDA ratio at 3.0x.
CapEx for 9M 2024 was €422 million, slightly lower year-over-year.
Outlook and guidance
FY 2024 EBITDA guidance narrowed to €1,000–1,250 million; mark-to-market EBITDA at €1.1 billion.
Free operating cash flow guidance remains at -€100 million to +€100 million.
Sales guidance narrowed to €14–14.5 billion; income tax expected at €150–300 million.
ROCE above WACC narrowed to -7 to -5 percentage points.
No significant margin rebound expected for the remainder of 2024.
Latest events from Covestro
- FY 2025 saw lower sales and earnings, but transformation and climate targets remain on track.1COV
Investor presentation26 Feb 2026 - EBITDA fell 30.9% to €740m as strategic actions and XRG partnership offset weak demand.1COV
Q4 2025 (Media)26 Feb 2026 - Sales and EBITDA declined sharply in FY 2025, but strategic initiatives and cost savings progressed.1COV
Q4 202526 Feb 2026 - Sales and EBITDA fell in Q3 2025, with guidance cut and acquisitions advancing.1COV
Q3 20253 Feb 2026 - Volume growth offset by lower prices; EBITDA fell and guidance narrowed as ADNOC talks progress.1COV
Q2 20242 Feb 2026 - €62/share offer and €1.17bn capital boost support growth, sustainability, and governance.1COV
Investor Update20 Jan 2026 - Stable EBITDA and volume growth offset price declines; XRG takeover and STRONG program drive outlook.1COV
Q4 20247 Jan 2026 - AGM approved all proposals amid a challenging year, XRG partnership, and no dividend for 2024.1COV
AGM 20252 Dec 2025 - Q1 sales steady, EBITDA fell on one-offs; 2025 outlook narrowed as transformation and XRG progress.1COV
Q1 202525 Nov 2025